Protego Biopharma, Inc. is a preclinical-stage biotechnology company based in San Diego, CA, dedicated to the discovery and development of small-molecule therapeutics for protein misfolding diseases. Their innovative approach focuses on reprogramming protein folding to treat various systemic amyloid diseases and other monogenetic protein misfolding diseases that cause a range of degenerative conditions.
With a team of experienced leaders and scientific advisors, Protego Biopharma utilizes a pharmacological chaperone screening platform and biomarker discovery to target unmet medical needs and enable precision medicine. Their goal is to address the loss of biological function and gain of toxicity caused by protein misfolding, ultimately improving patient outcomes and advancing the field of drug discovery in this area.
Generated from the website
